Phospholipid Autoantibodies (Nonanticardiolipin)-Antiprothrombin Antibodies

Francesca Pregnolato, Cecilia B. Chighizola

Research output: Chapter in Book/Report/Conference proceedingChapter


Prothrombin (PT) provides one of the main antigenic targets of antiphospholipid antibodies (aPL), the serologic markers of antiphospholipid syndrome (APS). First described in 1983, antibodies against PT (anti-PT) constitute the major contributor to lupus anticoagulant (LA) phenomenon. Anti-PT are currently best detected by homemade enzyme-linked immunosorbent assay (ELISA) assays, despite the many efforts made over the recent years to standardize detection methods. The prevalence of anti-PT is highly variable, depending on the selected study population: positivity rate ranges from 13.9% among systemic lupus erythematosus (SLE) subjects to 74% in LA-positive APS patients. Considering the strong correlation with LA, anti-PT have been proposed as LA confirming assays in case of ambiguous results and as an LA replacement test to overcome its technical limitations, like the interference with oral anticoagulation. Some authors have also suggested the inclusion of anti-PT in the laboratory criteria for APS diagnosis. However, the clinical relevance of anti-PT in both primary and secondary APS is still a matter of debate, with conflicting results about the association between anti-PT positivity and aPL-related clinical manifestations.

Original languageEnglish
Title of host publicationAutoantibodies: Third Edition
PublisherElsevier B.V.
Number of pages9
ISBN (Print)9780444563781
Publication statusPublished - Dec 2013


  • Antiphosphatidylserine/prothrombin antibodies
  • Antiphospholipid syndrome
  • Antiprothrombin antibodies
  • Lupus anticoagulant
  • Miscarriages
  • Thrombosis

ASJC Scopus subject areas

  • Immunology and Microbiology(all)


Dive into the research topics of 'Phospholipid Autoantibodies (Nonanticardiolipin)-Antiprothrombin Antibodies'. Together they form a unique fingerprint.

Cite this